Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review
Papillary renal cell carcinoma (pRCC) is the 2nd most frequent histological type of kidney cancer and accounts for approximately 15% of all renal cell carcinoma. It has a poorer prognosis than clear cell RCC (ccRCC) with a lack of standard treatments.
We report the case of a 51 year old man with a metastatic pRCC (hepatic dome and left colonic peritoneal carcinomatosis) progressive after sunitinib, with a MET amplification. The patient was enrolled in the UNICANCER-sponsored AcSé crizotinib trial (NCT02034981), designed to give an access to crizotinib for patients with tumors harboring a genomic alteration on one of the biological targets of the drug. With 2nd line crizotinib (250 mg twice/day), the patient had a very good tolerance, a partial response in the target lesions using RECIST 1.1, and a 19 months’ clinical efficacy.
In metastatic pRCC with a MET amplification, crizotinib maybe a potential met-inhibitory therapeutic option.
KeywordsPapillary renal cell carcinoma MET MET inhibitor Crizotinib Radiotherapy
- AcSé program
For “secure access to innovative targeted therapies”
Clear cell renal cell carcinoma
Eastern Cooperative Oncology Group
Mesenchymal epithelial transition proto-oncogene
Metastatic papillary renal cell carcinoma
Non small cell lung cancer
Papillary renal cell carcinoma
Renal cell carcinoma
Response evaluation criteria in solid tumors
Tyrosine kinase inhibitor
Papillary renal cell carcinoma (pRCC) is the 2nd most frequent histological type of kidney cancer and accounts for approximately 15% of all renal cell carcinoma (RCC). The classifications distinguish two types of pRCC: type 1 (more indolent, with basophilic cells) and type 2 (more aggressive, with eosinophilic cells). The prognosis of metastatic pRCC (mpRCC) is worse than in clear cell RCC (ccRCC), with a median PFS around 6 months and a median OS around 12 months, versus 10.5 months and 15.7 months respectively for ccRCC [1, 2]. For mpRCC, sunitinib or mTor inhibitors are proposed by NCCN Guidelines, but the inclusion in a clinical trial is the preferred option . MET protein is a heterodimer transmembrane Tyr-Kinase receptor, with one known ligand (Hepatocyte Growth Factor) and a signaling via MAP-Kinase pathway, leading to increase proliferative functions (invasion, aggressiveness, angiogenesis) . Anomalies of MET pathway have been described in several tumors (NSCLC, gastric, ovaries), and particularly in pRCC where 75% of hereditary pRCC have activating mutations in the Tyr/Kin domain [4, 5]. Here we present the case of a patient with a MET-amplified mpRCC successfully treated during 19 months with the MET-inhibitor crizotinib within the French AcSé- crizotinib program .
The patient was referred to our Comprehensive Cancer Center in April 2014, with a post-operative abdominal mass. His medical history included cigarette smoking (20 packs/year), thyroidectomy (supplementation), non-insulin-dependent mellitus diabetes (metformin) and hypertension (amlodipine, valsartan). Clinically, he weighed 78 kg for 1.80 m, Karnosky performance scale was 80% and physical examination revealed induration of the abdominal scar. The laboratory tests were normal (Hb = 14.6 g/dl, Neutrophil = 2.3 109/L, Platelets = 326 G/l, absence of hypercalcemia) and the patient was classified in the favorable-risk group according to Heng criteria. Repeat CT scan revealed peritoneal carcinomatosis.
In March 2015, the patient noticed a progression of a left painless inguinal adenopathy of 54 mm, without progression of the other peritoneal lesions and a normal bone scan. In accordance with the protocol, a volumetric-modulated radiotherapy delivered a dose 35 Gy (10 fractions of 3.5 Gy) and crizotinib was stopped from the day before to the day after the radiotherapy. In November 2015, the periodic CT scan revealed a new node relapse (left external iliac lymph nodes of 49 mm). A CT-guided biopsy confirmed the diagnosis of papillary renal cell carcinoma, that still expressed C-MET 100% (score 3+). Therefore, due to the success of the first treatment, a 2nd radiotherapy was performed (42.5 Gy).
On May 2016, after 19 months of crizotinib, a relapse was observed with ascites and the patient was treated with axitinib. Three months later, the patient died of progression.
Discussion and conclusion
MpRCC can be an aggressive disease with a lack of standard treatments, as the most classical drug in 1st line (sunitinib) was only studied in small phase II studies. In 2015, Ravaud et al. treated 61 patients with sunitinib (15 type 1 mpRCC / 46 type 2) with a modest median PFS of 6.6 months (type 1) and 5.5 months (type 2) and only 7/61 partial response . Moreover, mTOR inhibitor everolimus has been shown to be less efficient than sunitinib in non-ccRCC [7, 8]. Data concerning pazopanib are scarce .
Here, we present the case of a man with a mpRCC, progressive after sunitinib, for which the diagnosis of MET amplification led to use crizotinib in 2nd line with a 19 months’ efficacy, and a very good tolerance (ECOG 0, 100% professional activity). The multidisciplinary collaboration of pathologist, molecular biologist, radiation oncologist and medical oncologist led to this successful example of personalized medicine via MET targeting. Interestingly, Diamond et al. described a pRCC patient with an activating MET gene mutation, pretreated by sunitinib and everolimus, with a long response to a tyrosine kinase inhibitor (TKI: PF-04217903) . But this situation is rare in routine clinical practice, as MET copy number amplifications are more frequent in pRCC (81% of type 1 in the series of Albiges et al.) than intracellular domain MET mutations (21%) ; moreover the development of this TKI has stopped.
Biologically, the proof of MET implication in pRCC was made in 1997 with the discovery that hereditary pRCC patients had a germline missense mutation in the MET proto-oncogene (7q3 locus), leading to constitutive activation of the MET protein . Recently, a translational analysis of 220 pRCC revealed the presence of DNA copy number alterations (gain) in 46% of type 2 pRCC and in 81% of type 1 pRCC, significantly higher than in clear cell RCC . And it has been published earlier that gene copy number increase is associated with upregulation of MET protein expression . Another large series of pRCC (n = 164) described MET mutations in 17 tumors, mainly in type 1 pRCC and in the tyrosine kinase domain (14/17), and discovered an alternate MET RNA transcript leading to a constitutive activation of MET in a ligand-independent manner .
This biological evidence for the implication of MET in both hereditary and sporadic pRCC have led to design trials with MET inhibitors in pRCC [15, 16]. However, the preliminary results of MET targeting were disappointing. First, foretinib (MET/VEGFR2 inhibitor) was examined in a phase II including 74 patients with mpRCC: the median PFS was 9.3 months and patients with a germline mutation were significantly more likely to respond . No responses were observed in patients with MET-amplification (n = 2) and only 1/18 patients (5%) with a gain of chromosome 7 responded. Second, tivantinib (selective oral MET inhibitor) had very poor outcomes in PFS (median: 2 months) and OS (median 10 months) and had a 0% response rate (n = 70) . Thirdly, savolitinib (AZD6094 or volitinib, selective MET inhibitor) was recently tested in a single-arm, multicenter, phase II study (n = 109) . Interestingly, if the response rate was 0% in MET-independent pRCC, it was of 18% in patients with a MET-driven pRCC (chromosome 7 copy gain, focal MET or HGF gene amplification, or MET kinase domain mutations). To broaden this strategy of MET targeting, the SWOG 1500 (PAPMET trial, phase II) was designed as a multi-arm trial of three MET inhibitors (cabozantinib, volitinib or crizotinib) versus sunitinib . This trial will include 180 patients and the first results (primary outcome: PFS) are expected for 2020. Interestingly, several biomarkers are included in the trial, either integrated (MET mutation / MET expression) or exploratory (genomic profiling), which will add precious biological knowledge.
Concerning crizotinib, this treatment is a currently available MET-ALK-ROS1 inhibitor, with a favourable toxicity profile, and is well known by medical oncologists for the treatment of non-small cell lung cancer [21, 22]. At the time we treated this patient, no data was available concerning the efficacy of crizotinib in pRCC. Only a previous case report described a MET-mutated pRCC patient pre-treated with sunitinib and tivantinib ; however this mutation (missense base substitution MET H1094L) is rare compared to MET amplification, and the patient only remained on crizotinib therapy for 5 months (versus 19 months in our patient). Our report also highlights the feasibility and efficacy of a focal irradiation in the situation of a pRCC patients treated with crizotininb (with suspension of crizotinib from the day before to the day after radiotherapy). Interestingly, in November 2017 were published the results of pRCC1 patients included in the CREATE trial (EORTC 90101), a multicentric prospective phase II clinical trial including patients with tumors harboring specific alterations leading to ALK and/or MET activation and treated with crizotinib . Among the 4 MET-driven pRCC1 patients, the ORR was 50%, with a 1-year PFS rate = 75%, whereas among the 16 MET-independent pRCC1 patients, the ORR was 6.3% with a 1-year PFS rate = 27%. This study demonstrated that crizotinib is active in pRCC, achieving long-lasting disease control in patients with MET mutations or amplification.
Our case report illustrates and reinforces this finding that crizotinib is more active in MET driven pRCC, and that a precise molecular diagnosis is crucial for the optimal care of pRCC. This precision treatment (crizotinib) was possible thanks to an original biology-driven national French program (AcSé crizotinib NCT02034981), giving access to crizotinib for patients with identified activating genomic alterations in the crizotinib target genes, with a safe monitoring . Today, this academic national program (28 regional centers), enrolled more than 235 patients with refractory malignancies and no therapeutic alternative . In ASCO 2018, the results of AcSé crizotinib trials demonstrated the efficacy of crizotinib in chemo-refractory MET-amplified esogastric adenocarcinomas (ORR = 42.8%) . The data are not yet mature for a specific analysis of pRCC patients, but this case report and the data of CREATE study are promising results of precision medicine in pRCC.
In conclusion, the molecular documentation of MET in pRCC seems crucial, as MET inhibitors like crizotinib are effective, safe, and nowadays available.
We thank Emilie Agavnian-Couquiau for her help in the pathological scanning. We thank Brice Chanez for his help in the revision of the manuscript.
The French National Cancer Institute and Foundation ARC against cancer supported the Acsé Program (design of the study, data collection and data analysis). The Paoli Calmettes Institute supported the clinical facilities for patient’s diagnosis and treatment. No funding source were involved in the interpretation of data and the writing of the manuscript.
Availability of data and materials
The datasets used during the current study are in Institut Paoli Calmettes and are available from the corresponding author on reasonable request.
PR and GG designed the research and wrote the paper. JTP performed the histological examination and SL performed the FISH analysis. PR, JTP, SL, SB, NS, BE, GV and GG collaborated on the paper’s conception, reviewed the paper and approved the final version of the article to be published.
Ethics approval and consent to participate
The AcSé trial (NCT02034981) was approved by French ethics committee (name: CPP IDF VII – Hopitâl de Bicêre / reference number: 20013000–885-13).
Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
- 3.NCCN. NCCN clinical practice guidelines in oncology-kidney cancer. Available from: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. [cited 30 Jan 2017].
- 18.Twardowski P, Plets M. SWOG 1107: parallel (randomized) phase II evaluation of tivantinib (ARQ-197) and tivantinib in combination with erlotinib in patients (Pts) with papillary renal cell carcinoma (pRCC). J Clin Oncol:33(15_suppl). Available from: http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.4523. [cited 11 Oct 2018].
- 21.Shaw AT, S-HI O, Bang Y-J, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371:1963–71.Google Scholar
- 25.ClinicalTrials: phase 2 study assessing efficacy and safety of crizotinib in patients harboring an alteration on ALK, MET or ROS1 - Tabular View - ClinicalTrials.gov. Available from: https://clinicaltrials.gov/ct2/show/record/NCT02034981. [cited 10 Feb 2017].
- 26.Vassal G. Meeting Library | Biomarker-driven access to crizotinib in ALK, MET, or ROS1 positive (+) malignancies in adults and children: The French National AcSé Program. Available from: https://meetinglibrary.asco.org/record/158633/abstract. [cited 12 Oct 2018].
- 27.Aparicio T. Meeting Library | The activity of crizotinib in chemo-refractory MET-amplified esogastric adenocarcinomas: results from the AcSé-crizotinib program. Available from: https://meetinglibrary.asco.org/record/160162/abstract. [cited 12 Oct 2018].
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.